These results suggest that HSC‐specific Ash1l deletion can ameliorate hepatic fibrosis, while simultaneous depletion of Ash1l in both hepatocytes and HSCs is necessary to mitigate HCC development in vivo. The gene discussed is ASH1L; the disease is hepatocellular carcinoma.